Navigate IRP/ERP reference pricing networks across 40+ countries. Map how pharmaceutical pricing flows between regulatory bodies and forecast the impact of every launch decision before you commit.
Two interactive visualisations — no login required. Click and explore.
Every launch decision carries hidden pricing risk. GAiN makes the invisible visible.
GAiN delivers real-time intelligence across your portfolio — from IRP/ERP network effects to competitive white space and access trajectory forecasting.
Understand how a pricing decision in one market ripples across reference pricing networks. Identify cascade risks before launch sequencing locks you in.
Track reimbursement status for 202+ innovative drugs across 100+ markets. Five status tiers — from positive national coverage to white space opportunity.
Simulate launch sequences across markets. Identify which order maximises revenue while minimising IRP-driven price erosion across your global portfolio.
Benchmark price approval timelines country by country — from Switzerland's 6 months to France's 12.9 months — and forecast access trajectories with precision.
Join pharma and medtech teams already using GAiN to eliminate IRP blind spots and launch with precision.
Request Early Access